IntroductionThe LIM-only protein 2 (LMO2) is an essential transcriptional regulator in hematopoiesis, whose inappropriate regulation frequently contributes to the development of leukemia. LMO2 was initially cloned from a T-cell acute lymphoblastic leukemia (T-ALL) patient sample bearing a (t(11;14)(p13;q11)) translocation, 1,2 and its aberrant expression can be detected in 9% of all pediatric cases of T-ALL. 3 T-ALL is characterized by an accumulation in the bone marrow of immature T cells that are altered in their capacity to terminally differentiate. Ectopic activation of LMO2 is thought to initiate leukemia by promoting self-renewal of preleukemic thymocytes through reactivation of expression of hematopoietic stem cell-specific genes. 4 LMO2 has also been shown to be activated in T cells by retroviral insertion in a cohort of young patients undergoing gene therapy treatment for X-linked severe combined immunodeficiency syndrome, thereby deregulating its transcription and triggering clonal proliferation of thymocytes. 5 LMO2 belongs to a subset of the large zinc finger protein family, the LMO proteins. 6 LMO1, LMO2, LMO3, and LMO4 are characterized by the presence of 2 LIM domains (LIM1 and LIM2), each one of them composed of 2 zinc fingers. Despite the presence of zinc finger motifs, no in vivo interaction of LMO2 with DNA has been shown to date, whereas LMO2 interacts with a plethora of proteins. These include the bHLH protein SCL/Tal1, thought to act synergistically with LMO2 in hematopoietic development and, like LMO2, involved in the pathophysiology of T-ALL, 7-12 SCL's heterodimerization partner E2A (E47/E12), the hematopoietic transcription factors GATA-1/2, 13 AF6, the fusion partner of chromatin remodeling and leukemogenic protein MLL, 14 and the LIM-domain interacting protein LDB1. 15,16 LMO proteins are thought to act as scaffolding proteins involved in multiprotein complex formation in a myriad of developmental processes through their interaction with LDB1. 9,17,18 LDB1 is a widely expressed nuclear adaptor protein that dimerizes through its N-terminal domain and binds LMO proteins and several other LIM homeodomains through its C-terminal LID domain (LIM-interacting domain). 19 Dimerization of LDB1 is thought to give rise to various multiple competitive binding events in which different tetrameric or higher-order complexes with LMO and LIM homeodomains are created in different cell types, specifying distinct cell fates. 20 Differences in affinities of LMO proteins for LDB1 are at the basis of the delicate equilibrium of complex formation, needed for correct transcriptional control. Enforced expression of LMO2 by chromosomal translocations or transgenesis may cause T-cell tumorigenesis, for example, by displacement of LMO4 as the normal binding partner of LDB1 in maturing T cells. 21 Loss-of-function studies in mouse and zebrafish have revealed critical functions for LMO2 in the establishment of primitive and definitive hematopoiesis during embryonic development. 12,22,23 In normal blood development...